Heteromers of amyloid precursor protein in cerebrospinal fluid

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Cuchillo Ibañez, Inmaculada ^a,b   Lopez Font, Inmaculada ^a,b   Boix Amorós, Alba ^a   Brinkmalm, Gunnar ^c   Blennow, Kaj ^c   Molinuevo, Jose Luis ^d   Sáez Valero, Javier ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; ELISA; Heteromers; SAPP ; SAPP

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; OLIGOMER; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; SECRETASE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; OLIGOMERIZATION; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; SUCROSE DENSITY GRADIENT CENTRIFUGATION; ULTRACENTRIFUGATION; CELL CULTURE; CEREBROSPINAL FLUID; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOMARKERS; CELLS, CULTURED; HUMANS; IMMUNOPRECIPITATION; TAU PROTEINS;

EID: 84964695079     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-10-2     Document Type: Article

References (47)

1. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615-9.
2. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090-8.
3. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gammasecretase. J Biol Chem. 2008;283:29627-31.
4. Palmert MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan HW, et al. The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A. 1989;86:6338-42.
5. Ghiso J, Tagliavini F, Timmers WF, Frangione B. Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. Biochem Biophys Res Commun. 1989;163:430-7.
6. Perneczky R, Alexopoulos P, Kurz A. Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends Mol Med. 2014;20:8-15.
7. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res. 2010;1357:175-83.
8. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry. 2010;15:138-45.
9. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, et al. Cerebrospinal Fluid Levels of sAPPalpha and sAPPbeta in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. Int J Alzheimers Dis. 2011;2011:495025.
10. Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, Westerteicher C, et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement. 2012;8:304-11.
11. Efthimiopoulos S, Vassilacopoulou D, Ripellino JA, Tezapsidis N, Robakis NK. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci U S A. 1996;93:8046-50.
12. Tezapsidis N, Li HC, Ripellino JA, Efthimiopoulos S, Vassilacopoulou D, Sambamurti K, et al. Release of nontransmembrane full-length Alzheimer's amyloid precursor protein from the lumenar surface of chromaffin granule membranes. Biochemistry. 1998;37:1274-82.
13. Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, et al. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem. 2001;276:33923-9.
14. Nyabi O, Bentahir M, Horré K, Herreman A, Gottardi-Littell N, Van Broeckhoven C, et al. Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem. 2003;278:43430-6.
15. Tanaka S, Nakamura S, Ueda K, Kameyama M, Shiojiri S, Takahashi Y, et al. Three types of amyloid protein precursor mRNA in human brain: their differential expression in Alzheimer's disease. Biochem Biophys Res Commun. 1988;157:472-9.
16. Evin G, Li QX. Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J Psychiatry. 2012;2:102-13.
17. Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Portbury S, et al. Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem. 1988;273:5013-9.
18. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990;265:15977-83.
19. Gardella JE, Ghiso J, Gorgone GA, Marratta D, Kaplan AP, Frangione B, et al. Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem Biophys Res Commun. 1990;173:1292-8.
20. Ripellino JA, Vassilacopoulou D, Robakis NK. Solubilization of full-length amyloid precursor proteins from PC12 cell membranes. J Neurosci Res. 1994;39:211-8.
21. Barao S, Zhou L, Adamczuk K, Vanhoutvin T, van Leuven F, Demedts D, et al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res. 2013;10:671-8.
22. García-Ayllón MS, Campanari ML, Brinkmalm G, Rábano A, Alom J, Saura CA, et al. CSF Presenilin-1 complexes are increased in Alzheimer's disease. Acta Neuropathol Commun. 2013;1:46.
23. Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, et al. Homo and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 2005;24:3624-34.
24. Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 2013;125:201-13.
25. Pottier C, Wallon D, Lecrux AR, Maltete D, Bombois S, Jurici S, et al. Amyloidbeta protein precursor gene expression in alzheimer's disease and other conditions. J Alzheimers Dis. 2012;28:561-6.
26. Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Pratley RE. Measurement of altered AbetaPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. J Alzheimers Dis. 2012;29:449-57.
27. Taverna M, Straub T, Hampel H, Rujescu D, Lichtenthaler SF. A new sandwich immunoassay for detection of the alpha-secretase cleaved, soluble amyloid-beta protein precursor in cerebrospinal fluid and serum. J Alzheimers Dis. 2013;37:667-78.
28. Lewczuk P, Popp J, Lelental N, Kölsch H, Maier W, Kornhuber J, et al. Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis. 2012;28:119-25.
29. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Förstl H, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology. 2011;77:35-8.
30. Hock C, Golombowski S, Müller-Spahn F, Naser W, Beyreuther K, Mönning U, et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid betapeptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. Eur Neurol. 1998;39:111-8.
31. Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, et al. Measurement of alpha and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol. 2003;183:74-80.
32. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65:1102-7.
33. Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, et al. Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease. Brain Res. 2013;1513:117-26.
34. Prior R, Mönning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, et al. Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett. 1991;124:69-73.
35. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000;278:169-72.
36. Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992;89:2551-5.
37. Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular Med. 2012;14:65-73.
38. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419-30.
39. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9:251-61.
40. Steinacker P, Fang L, Kuhle J, Petzold A, Tumani H, Ludolph AC, et al. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One. 2011;6:e23600.
41. Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jørgensen HL, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord. 2012;18:69-72.
42. Kitazume S, Yoshihisa A, Yamaki T, Oikawa M, Tachida Y, Ogawa K, et al. Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Biol Chem. 2012;287:40817-25.
43. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, et al. Cerebrospinal fluid biomarkers of beta-amyloid metabolism in multiple sclerosis. Mult Scler. 2013;19:543-52.
44. Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol. 2013;260:620-6.
45. Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landén M. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology. 2013;38:664-72.
46. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
47. Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, et al. Enhanced production and oligomerization of the 42-residue amyloid betaprotein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272:7977-8.